What You Need to KnowBackground and ContextIntestinal epithelial homeostasis depends on a tightly regulated balance between intestinal epithelial cell (IEC) death and proliferation. While the disruption of several IEC death regulating factors result in intestinal inflammation, the loss of the anti-apoptotic BCL2 family members BCL2 and BCL2L1 has no effect on intestinal homeostasis in mice.New FindingsThe BCL2 family member MCL1 is required for maintenance of intestinal homeostasis and prevention of carcinogenesis in mice. Loss of MCL1 results in intestinal carcinogenesis---even under germ-free conditions, and therefore does not involve microbe-induced chronic inflammation.LimitationsThis study was performed in mice. Studies are needed to determine whether MCL1 function is disrupted in patients with inflammatory bowel diseases or cancer.Impact*Mcl1*^ΔIEC^ mice might be used to study apoptotic enterocolopathy and inflammatory bowel diseases.

Intestinal homeostasis is dependent on a tightly regulated interaction among the epithelium, the immune system, and luminal commensal bacteria. The intestinal epithelium compartment is composed of different cell types, including proliferative stem cells as well as highly specialized absorptive (enterocytes) and secretory cells (goblet, Paneth, and neuroendocrine cells).[@bib1]^,^[@bib2] These intestinal epithelial cells (IECs) provide a physical barrier between the intestinal mucosa and potentially pathogenic microorganisms. IECs display a high cell turnover, necessitating a strictly regulated balance of proliferation and cell death to guarantee intestinal epithelial homeostasis[@bib3]; however, excessive IEC death is a well-known clinical hallmark of apoptotic enterocolopathy and inflammatory bowel disease (IBD).[@bib3], [@bib4], [@bib5]

In recent years, there has been great scientific interest in determining the roles played by cell death regulating molecules in maintaining tissue homeostasis and preventing tumorigenesis. Transgenic mice, generated with intestinal-specific knockouts of particular IEC circuits of regulated cell death, FADD, Caspase 8, or RIPK1, display excessive IEC turnover, epithelial defects and IBD-like inflammation.[@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11] In contrast, mice harboring intestinal-specific deletions of other regulated cell death molecules, BCL2 or BCL2L1, display surprisingly little pathology under steady-state conditions. Although capable of modulating intestinal carcinogenesis in tumor models, both are dispensable for maintaining intestinal homeostasis.[@bib12]^,^[@bib13] Interestingly, another pro-survival BCL2 family member, MCL1, is essential for maintaining homeostasis in several tissues with regenerative capacity.[@bib14], [@bib15], [@bib16] The indispensable role for MCL1 in maintaining liver homeostasis[@bib15]^,^[@bib16] prompted us to study its function in the intestinal tract.

Materials and Methods {#sec1}
=====================

Mice {#sec1.1}
----

Housing and experimental procedures of all animals were performed in accordance with the Cantonal Veterinary Office (Zurich, Switzerland) under the license numbers ZH217/12 and ZH166/15 or the UK Home Office regulations (licence 70/8646) according to ARRIVE guidelines. Animals were maintained under specific pathogen free (SPF) conditions at the University of Zurich or at the CRUK Beatson Institute, Glasgow ([Supplementary Table 1](#appsec1){ref-type="sec"}). Germ-free housing of mice was performed within the Clean Mouse Facility of the University of Bern.[@bib17] A detailed description of the generation of each mouse line is provided in the [Supplementary Material](#appsec1){ref-type="sec"}.

Antibiotic (ABX) Treatment {#sec1.2}
--------------------------

Ciprofloxacin (200 mg/L) (Fluka; Buchs, Switzerland), ampicillin sodium (1 g/L) (Sigma; St. Louis, MO), metronidazole (1 g/L) (Fluka), and vancomycin HCl (500 mg/L) (Fluka) were added to the drinking water of cohoused, 1-month-old wild-type control and *Mcl1*^ΔIEC^ mice for 4 weeks.[@bib18]

Innate Lymphoid Cell (ILC) Depletion {#sec1.3}
------------------------------------

Two-month-old *Mcl1*^ΔIEC^*Rag1*^−/−^ mice were treated with α-Thy1.2--depleting antibody (200 μg) (BioxCell -- clone:30H12) or appropriate isotype control via intraperitoneal injection, 3 times per week for 4 weeks.

WNT Signaling Inhibition {#sec1.4}
------------------------

i-*Mcl1*^ΔIEC^ mice or wild-type controls received 5 mg/kg of WNT974 (provided via an material transfer agreement (MTA) with Novartis) orally, twice per day, in a 0.5% methylcellulose, 0.5% tween 80 vehicle.

BrdU Proliferation Analysis {#sec1.5}
---------------------------

BrdU (Amersham Biosciences; Buckinghamshire, UK) was administered via intraperitoneal injection 2 hours before mice were killed. The number of BrdU-positive crypts was determined by calculating the average number of BrdU-positive crypt cells per half crypt from 50 individual crypts.

Intestinal Epithelial Barrier Permeability {#sec1.6}
------------------------------------------

Intestinal epithelial barrier permeability was measured using fluorescein isothiocyanate--labeled dextran (FD-4) as previously described.[@bib19] Serum expression of FD-4 was determined using a BioTek Microplate Reader (BioTek; Winooski, VT).

Endoscopy {#sec1.7}
---------

Direct visualization of colonic mucosal damage of wild-type and *Mcl1*^ΔIEC^ mice was performed via high-resolution endoscopy using a "Coloview system" (Karl Storz, Tuttlingen, Germany). Mice were provided with food and water as normal until the endoscopy was performed. Isoflurane inhalation (2.0%--2.5%) in oxygen was used to anesthetize the mice for the duration of the procedure.

Calprotectin Analysis {#sec1.8}
---------------------

Calprotectin (S100A8 and S100A9) levels were determined from homogenates of colon tissue (real-time polymerase chain reaction) or feces (enzyme-linked immunosorbent assay). Calprotectin primer sequences: *S100A8* - Forward AAATCACCATGCCCTCTACAAG and Reverse CCCACTTTTATCACCATCGCAA, *S100A9* -- Forward ATACTCTAGGAAGGAAGGACACC and Reverse TCCATGATGTCATTTATGAGGGC. Reference gene (*Gapdh)* - Forward CCACCCCAGCAAGGAGACT and Reverse GAAATTGTGAGGGAGATGCT. Protein levels of Calprotectin (S100A8 and S100A9) were determined by enzyme-linked immunosorbent assay (Immune Diagnostik, \#K6936; Bensheim, Germany).

Histology {#sec1.9}
---------

Formalin-fixed tissue was embedded in paraffin. Paraffin sections were rehydrated and heat-induced antigen retrieval was performed in either Tris/EDTA/BORAT or citrate buffer. Incubation in Ventana buffer and staining was performed on a BenchmarkUltra immunohistochemistry robot (Ventana Instruments) using Chromo Map or Optiview Dab Detection Kits (Ventana) or on a Bond MAX (Leica, Wetzlar, Germany). All primary antibodies used for immunohistochemistry are listed in [Supplementary Table 2](#appsec1){ref-type="sec"}. A detailed description of the criteria used for the histological scoring is available in the [Supplementary Material](#appsec1){ref-type="sec"} ([Supplementary Table 3](#appsec1){ref-type="sec"}).

Tumor Classification {#sec1.10}
--------------------

Hematoxylin and eosin--stained slides of intestinal lesions, blinded for genotype and housing conditions, were independently evaluated by 2 pathologists. Tumor classification was based on established nomenclature and criteria for the histologic assessment of intestinal tumors in mice.[@bib20] According to the criteria for the classification of human intestinal tumors, a small bowel neoplasm with infiltrative growth in the mucosa was classified as a carcinoma.[@bib21] In cases in which mice developed multiple tumors, classification was performed according to the highest lesion.

In Situ Hybridization {#sec1.11}
---------------------

In situ hybridization was performed on formalin-fixed paraffin-embedded (FFPE) tissues according to the manufacturer\`s protocol using 4 commercially available probes. A detailed description of all probes used in this study can be found in the [Supplementary Material](#appsec1){ref-type="sec"}.

Ex Vivo Cytokine Expression Analysis {#sec1.12}
------------------------------------

Ex vivo cytokine analysis was performed using supernatant recovered from colon cultures as previously described.[@bib22] Supernatant was collected after 48 hours, and cytokine expression was determined using Multiplex analysis kits (Bio-Rad Laboratories, Hercules, CA) and read using Bio-Plex MAGPIX Multiplex Reader powered by Luminex XMAP Technology (Bio-Rad Laboratories).

Sequencing {#sec1.13}
----------

Genomic DNA was isolated from FFPE tissue blocks using Macherey & Nagel's (Duren, Germany) NucleoSpin FFPE Kit and analyzed by Sanger sequencing or whole exome sequencing. A detailed description of the sequencing protocols used are available in the [Supplementary Material](#appsec1){ref-type="sec"}.

RNA-sequencing (RNASeq) analysis was performed on RNA extracted from whole small intestine tissue of i-*Mcl1*^ΔIEC^ mice (4 days post deletion) or i-*Apc*^ΔIEC^ and i-*Apc*^ΔIEC^*Mcl1*^ΔIEC^ mice (3 days post deletion). A detailed description of the RNASeq protocol is provided in the [Supplementary Tables 4--9](#appsec1){ref-type="sec"}. Gene set enrichment analysis (GSEA) was performed using the GSEA v2.0 software (Broad Institute). The comparison gene sets were obtained from published sources; genes upregulated following APC loss[@bib23] and WNT target genes commonly upregulated in human colorectal cancer.[@bib24]

Single Molecule Fluorescence In Situ Hybridization (smFISH) {#sec1.14}
-----------------------------------------------------------

smFISH was performed as previously described.[@bib25] A comprehensive description of the protocol, including quantification and probes used ([Supplementary Tables 10--12](#appsec1){ref-type="sec"}), is provided in the [Supplementary Material](#appsec1){ref-type="sec"}.

Statistical Analysis {#sec1.15}
--------------------

Statistical analyses were conducted as indicated within each figure legend. For all analyses, ∗*P* ≤ .05, ∗∗*P* ≤ .01, ∗∗∗*P* ≤ .001. Statistical analyses were conducted using GraphPad Prism 5/7 software (La Jolla, CA).

Results {#sec2}
=======

MCL1 Is a Key Regulator of Intestinal Homeostasis {#sec2.1}
-------------------------------------------------

To unravel the physiological role of MCL1 within the intestinal tract, we generated mice with an IEC-specific deletion of *Mcl1* (*Mcl1*^ΔIEC^ mice) ([Supplementary Figure 1](#appsec1){ref-type="sec"}*A*). Compared with littermate controls, *Mcl1*^ΔIEC^ mice developed extensive diarrhea, reduced weight gain, and significantly increased mortality ([Figure 1](#fig1){ref-type="fig"}*A*). Colonoscopies performed on 4-month-old *Mcl1*^ΔIEC^ mice revealed extensive thickening and whitening of the colonic wall and distinct polyp formation ([Figure 1](#fig1){ref-type="fig"}*A*). Furthermore, 2-month-old *Mcl1*^ΔIEC^ mice displayed an impaired epithelial barrier function, as demonstrated by increased permeability of orally administered fluorescein isothiocyanate--labeled dextran ([Figure 1](#fig1){ref-type="fig"}*B*). Elevated levels of S1008/S1009 (calprotectin), a biomarker of intestinal inflammation, were also detected in stool samples and tissue homogenates from *Mcl1*^ΔIEC^ mice ([Figure 1](#fig1){ref-type="fig"}*C*).Figure 1MCL1 is essential for maintaining intestinal homeostasis. (*A*) *Mcl1*^ΔIEC^ mice show reduced weight gain (n = 50) and survival (n = 126) compared with littermate controls (n = 34 and n = 61, respectively). Representative colonoscopy images from 4-month-old mice. (*B*) Two-month-old *Mcl1*^ΔIEC^ mice display increased serum levels of FITC dextran (n = 13) compared with littermate controls (n = 8) 4 hours after oral administration. (*C*) Calprotectin (S100A8/S100A9) levels of 2-month-old *Mcl1*^ΔIEC^ mice and age-matched controls by enzyme-linked immunosorbent assay (ELISA) (n = 6 *Mcl1*^ΔIEC^ mice, n = 9 wild type) or real-time polymerase chain reaction (n = 8 *Mcl1*^ΔIEC^ mice, n = 5 wild type). (*D*) Representative images illustrating *Mcl1* expression in the colon (*red stain*) as demonstrated using in situ hybridization (scale bars: 100 μm). (*E*) Representative images from the colon of two-month-old *Mcl1*^ΔIEC^ mice compared with age-matched controls (scale bars: 100 μm , 25 μm-inserts). (*F*) Blinded histological scores comparing the colon of 2-month-old *Mcl1*^ΔIEC^ mice with littermate controls (n = 5). (*G*) Colon cultures established from 2-month-old mice and analyzed using multiplex analysis (minimum n = 10 per group). Data presented as either bar charts or scatter plot graph show mean values ± SEM. Statistical analyses were conducted by 1-way analysis of variance with Bonferroni correction (*A* \[body weight\], *G*), log rank (Mantel-Cox test) (*A*, survival), Student *t* test (*B* and *C*), or Mann-Whitney test (*F*), where ∗*P* ≤ .05, ∗∗*P* ≤ .01, ∗∗∗*P* ≤ .001.

Interestingly, not all IECs within *Mcl1*^ΔIEC^ mice underwent *Mcl1* recombination and subsequently *Mcl1*^ΔIEC^ mice displayed areas that retained *Mcl1* expression alongside areas of *Mcl1* deficiency. Consequently, areas of severe mucosal damage appeared alongside histologically normal regions of both the small intestine and colon. Interestingly, IECs in histologically normal mucosal regions retained *Mcl1* messenger RNA expression, whereas IECs from damaged mucosal regions lacked *Mcl1* ([Figure 1](#fig1){ref-type="fig"}*D*). Furthermore, S1008/S1009 levels were inversely correlated with *Mcl1* expression, indicating the severity of intestinal damage was closely correlated with *Mcl1* deficiency ([Supplementary Figure 1](#appsec1){ref-type="sec"}*B*). Histopathological analysis of 2-month-old *Mcl1*^ΔIEC^ mice showed architectural disarray with crypt hyperplasia, villous atrophy (small intestine), increased IEC apoptosis (rather than necroptosis) (cleaved caspase 3), and hyperproliferative crypts (Ki-67) throughout both the colon and small intestine ([Figure 1](#fig1){ref-type="fig"}*E* and *F*, [Supplementary Figure 1](#appsec1){ref-type="sec"}*C--F*). Notably, deleting a single copy of the *Mcl1* gene was not sufficient to induce the histopathological damage observed in *Mcl1*^ΔIEC^ mice ([Supplementary Figure 2](#appsec1){ref-type="sec"}*A*).

MCL1 Deficiency Results in Microbiota-induced Chronic Inflammation {#sec2.2}
------------------------------------------------------------------

In addition to the impaired epithelial barrier function described previously, we also observed a marked decrease in the protective mucus layer at the intestinal mucosal barrier as well as extensive bacterial translocation from the lumen into the mucosa in *Mcl1*^ΔIEC^ mice ([Supplementary Figure 3](#appsec1){ref-type="sec"}*A*). Taken together, we concluded that MCL1 deficiency resulted in major epithelial cell dysfunction and chronic intestinal inflammation. Indeed, large lymphoid follicles, comprising mainly B and T cells, as well as an increased number of infiltrating immune cells, were detected within the mucosa of *Mcl1*^ΔIEC^ mice ([Supplementary Figure 4](#appsec1){ref-type="sec"}*A*). In addition, proinflammatory cytokines TNF-α, interleukin (IL)-22, IL-23A, IL-17A, IL-17F and IL-1β were significantly in *Mcl1*^ΔIEC^ mice ([Figure 1](#fig1){ref-type="fig"}*G* and [Supplementary Figure 4](#appsec1){ref-type="sec"}*B*). To determine the contribution of adaptive immune cells to mucosal inflammation and subsequent pathology following *Mcl1* deletion, *Mcl1*^ΔIEC^ mice were inter-crossed with *Rag1*^−/−^ mice (*Mcl1*^ΔIEC^*Rag1*^−/−^ mice). Unexpectedly, *Mcl1*^ΔIEC^*Rag1*^−/−^ mice exhibited significantly reduced weight gain and shorter survival compared with both wild-type and *Mcl1*^ΔIEC^ mice ([Figure 2](#fig2){ref-type="fig"}*A*). In addition, *Mcl1*^ΔIEC^*Rag1*^−/−^ mice also retained increased IEC apoptosis, hyperproliferative crypts, extensive mucosal damage ([Figure 2](#fig2){ref-type="fig"}*B* and *C*, [Supplementary Figure 5](#appsec1){ref-type="sec"}*A* and *B*), and elevated levels of proinflammatory cytokines despite lacking conventional T cells ([Figure 2](#fig2){ref-type="fig"}*D*, [Supplementary Figure 5](#appsec1){ref-type="sec"}*C* and *D*). Given the observed cytokine profile, we postulated that ILCs[@bib26] were driving chronic intestinal inflammation, at least in the absence of conventional T cells. To test this hypothesis, ILCs were depleted in 2-month-old *Mcl1*^ΔIEC^*Rag1*^−/−^ mice following a 4-week treatment with α-Thy1.2 antibody. Thy1 (CD90) positive cell depletion ([Supplementary Figure 6](#appsec1){ref-type="sec"}*A*) improved MCL1 deficiency--associated damage and resulted in the significant reduction of proinflammatory cytokines IL-22 and IL-17F ([Figure 2](#fig2){ref-type="fig"}*E* and *F*, [Supplementary Figure 6](#appsec1){ref-type="sec"}*B*); however, increased IEC apoptosis and hyperproliferation persisted after ILC depletion ([Figure 2](#fig2){ref-type="fig"}*E*). Thus, by showing that MCL1 is indispensable for intestinal homeostasis, we identified a novel function for MCL1, not observed for family members BCL2 and BCL2L1.[@bib12]^,^[@bib13]Figure 2MCL1 deficiency--associated chronic inflammation is mediated by ILCs. (*A*) Genetic depletion of *Rag1* within *Mcl1*^ΔIEC^ mice significantly reduced weight gain and survival (n = 19). *Blue asterisk*: *Mcl1*^ΔIEC^ mice compared with littermate controls, *red asterisk*: *Mcl1*^ΔIEC^*Rag1*^−/−^ mice compared with littermate controls, *purple asterisk*: *Mcl1*^ΔIEC^ mice compared with *Mcl1*^ΔIEC^*Rag1*^−/−^ mice. (*B*) Representative images from the colon of 2-month-old *Rag*1^−/−^ control mice compared with *Mcl1*^ΔIEC^*Rag*1^−/−^ mice showing impaired intestinal architecture (hematoxylin and eosin \[H&E\]), increased IEC apoptosis (cl. casp. 3) and hyperproliferation (Ki-67) (scale bars: 100 μm, 25 μm-inserts). (*C*) Blinded histological scores comparing 2-month-old *Mcl1*^ΔIEC^*Rag1*^−/−^ mice with *Rag*1^−/−^ mice (n = 5). (*D*) Colon cultures established from 2-month-old mice and analyzed using multiplex analysis (minimum n = 8 per group). (*E*) Representative images from colons of 3-month-old *Mcl1*^ΔIEC^*Rag1*^−/−^ mice following 4 weeks of α-Thy1.2 depleting antibody or corresponding isotype administration (scale bars: 100 μm, 25 μm-inserts). (*F*) Colon cultures established from 3-month-old mice and analyzed for TNF-α, IL-22, IL-23A, IL-17A, IL-17F, and IL-1β expression using multiplex analysis (minimum n = 8 per group). Data presented as either bar charts or scatter plot graph show mean values ± SEM. Statistical analyses were conducted by 1-way analysis of variance with Bonferroni correction (*A* \[body weight\], *D* and *F*), log rank (Mantel-Cox test) (*A*, survival) or Mann-Whitney test (*C*) where ∗*P* ≤ .05, ∗∗*P* ≤ .01, ∗∗∗*P* ≤ .001.

Increased IEC Apoptosis and Hyperproliferation Are a Direct Consequence of Mcl1 Deletion {#sec2.3}
----------------------------------------------------------------------------------------

To delineate whether the increased IEC apoptosis and hyperproliferation observed in *Mcl1*^ΔIEC^ mice were caused by the aforementioned chronic inflammation, or a direct result of MCL1 deficiency, *Mcl1*^ΔIEC^ mice were either placed under antibiotic treatment (ABX),[@bib18] or re-derived under germ-free conditions[@bib17] ([Supplementary Figure 7](#appsec1){ref-type="sec"}*A* and *B*). Following 4 weeks of ABX treatment, 2-month-old *Mcl1*^ΔIEC^ mice showed attenuated damage and significantly reduced intestinal inflammation compared with untreated *Mcl1*^ΔIEC^ mice ([Supplementary Figure](#appsec1){ref-type="sec"} 8*A*); however, ABX-treated *Mcl1*^ΔIEC^ mice retained increased IEC apoptosis and hyperproliferative crypts ([Supplementary Figure 8](#appsec1){ref-type="sec"}*A*). Similarly, germ-free *Mcl1*^ΔIEC^ mice displayed increased mucosal healing and a distinct lack of the immune cell infiltration observed in SPF *Mcl1*^ΔIEC^ mice ([Figure 3](#fig3){ref-type="fig"}*A* and *B*, [Supplementary Figures 8](#appsec1){ref-type="sec"}*B* and *C* and 9*A* and *B*). *Mcl1* deletion under germ-free conditions did not result in increased proinflammatory cytokine production when compared with littermate controls, despite evidence suggesting an impaired intestinal epithelial barrier ([Figure 3](#fig3){ref-type="fig"}*C*, [Supplementary Figures 8](#appsec1){ref-type="sec"}*D* and [10](#appsec1){ref-type="sec"}*A*); however, ameliorating chronic intestinal inflammation did not prevent the increased IEC apoptosis or hyperproliferation associated with *Mcl1* deletion ([Figure 3](#fig3){ref-type="fig"}*A*, [Supplementary Figure 8](#appsec1){ref-type="sec"}*B*). Collectively, these data show that whereas MCL1 deficiency--related chronic inflammation was due to an uncontrolled immune response against disseminating microbiota, increased IEC apoptosis and hyperproliferation directly result from MCL1 deficiency.Figure 3IEC apoptosis and hyperproliferation are a direct consequence of *Mcl1* deletion. (*A*) Representative images from the colon of 2-month-old germ-free *Mcl1*^ΔIEC^ mice compared with littermate controls illustrating increased IEC apoptosis (cl. casp. 3) and hyperproliferation (Ki-67) (scale bars: 100 μm, 25 μm-inserts). (*B*) Blinded histological scores comparing 2-month-old *Mcl1*^ΔIEC^ mice with littermate controls under germ-free conditions (n = 5 per group). (*C*) Colon cultures established from 2-month-old germ-free mice and analyzed using multiplex analysis (minimum n = 15 per group). Data presented as either bar charts or scatter plot graphs represents mean values ± SEM. Statistical analyses were conducted by Mann-Whitney test (*B*) or by 1-way analysis of variance with Bonferroni correction (*C*) where ∗*P* ≤ .05.

MCL1 Is Essential for Intestinal Stem Cell Homeostasis and Differentiation {#sec2.4}
--------------------------------------------------------------------------

Morphological analysis of the crypt compartments ([Figure 1](#fig1){ref-type="fig"}*E*) suggested that cellular compartmentalization was significantly dysregulated throughout the small intestine and colon of *Mcl1*^ΔIEC^ mice. Indeed, immunohistochemical analysis revealed that, following *Mcl1* deletion, intestinal stem cells (ISCs) were not capable of differentiating toward secretory lineages. *Mcl1*^ΔIEC^ mice showed a complete loss of both goblet (Alcian blue/periodic acid--Schiff positive) and Paneth cells (Lysozyme positive) in damaged (MCL1 deficient) areas ([Figure 4](#fig4){ref-type="fig"}*A--C* and [Supplementary Figure 11](#appsec1){ref-type="sec"}*A*). Of note, in unaffected areas (MCL1 positive), ISCs retained their differentiation capabilities, and produced both goblet and Paneth cells at a comparable rate to control mice ([Figure 4](#fig4){ref-type="fig"}*B* and *C*). Impaired ISC differentiation was also observed in affected compartments of germ-free *Mcl1*^ΔIEC^ mice, delineating the necessity for MCL1 in retaining intestinal homeostasis and ISC differentiation from chronic inflammation.Figure 4MCL1 is essential for ISC differentiation. (*A*) Representative images from the small intestine of 2-month-old *Mcl1*^ΔIEC^ mice compared with age-matched controls illustrating impaired goblet (Alcian blue/periodic acid--Schiff \[AB/PAS\]) and Paneth cell (lysozyme) differentiation, increased proliferation (Ki-67) and retention of stem cell markers (OLFM4 and SOX9) (scale bars: 100 μm). (*B*) Quantification of total goblet (AB/PAS) and Paneth cells (lysozyme) in the small intestine. (*C*) Quantification of total goblet (AB/PAS) cells in the colon. (*D*) Representative images from the small intestine of *Mcl1*^ΔIEC^ mice visualizing *Atoh1* expression in *Mcl1*-positive versus *Mcl1*-deficient IECs using smFISH. *White dots* represents single molecules of *Atoh1* and *red dots* represent *Mcl1.* ∗Indicates overexposed nonspecific signal. **Green boxes** mark the areas shown in higher magnification below (scale bars: 25 μm-upper, 10 μm-lower). (*E*) Quantification of *Atoh1* smFISH signal (n = 7 per group). Data presented as either bar charts or scatter plot graph show mean values ± SEM. Statistical analyses were conducted by Mann-Whitney test (*B, C,* and *E*) where ∗∗∗*P* ≤ .001.

Interestingly, MCL1-deficient undifferentiated and hyperproliferative cells also retained the ISC markers OLFM4, SOX9, and *Lgr5* (restricted to the base of the crypts under steady-state conditions) throughout mid to apical parts of crypts ([Figure 4](#fig4){ref-type="fig"}*A* and [Supplementary Figure 11](#appsec1){ref-type="sec"}*B*). To elucidate the molecular basis of this impaired ISC differentiation, we focused on the expression of *Atoh1,* an essential transcription factor for the differentiation of ISC toward the secretory cell lineages.[@bib27] Interestingly, we observed a significant reduction in *Atoh1* expression in *Mcl1*-deficient ISCs compared with *Mcl1*-positive ISCs within the same mouse using smFISH ([Figure 4](#fig4){ref-type="fig"}*D* and *E* and [Supplementary Figure 12](#appsec1){ref-type="sec"}*A* and *B*). These results suggest that, in the absence of MCL1, the axis of ISC proliferation and differentiation is constrained and polarized toward a highly proliferative ISC-dominant environment.

Given the well-established connection among hyperproliferation, replicative stress, and DNA damage,[@bib16]^,^[@bib28] we next sought to look for evidence of DNA damage accumulation. Immunohistochemical staining for the DNA damage response marker γH2AX, revealed strong positivity within the crypts of *Mcl1*^ΔIEC^ mice. γH2AX positivity was consistently found in *Mcl1*-deficient IEC but not in *Mcl1*-expressing IEC or IEC of littermate controls ([Supplementary Figure 13](#appsec1){ref-type="sec"}*A* and *B*). Furthermore, γH2AX positivity was also observed under germ-free conditions, independent of chronic inflammation. Altogether, MCL1 deficiency restricts ISCs to an undifferentiated and hyperproliferative state that makes the ISC susceptible to the accumulation of DNA damage.

MCL1-deficiency--Associated ISC Hyperproliferation Is Dependent on WNT Signaling {#sec2.5}
--------------------------------------------------------------------------------

To further investigate the direct consequences of *Mcl1* deletion and how it translates to IEC hyperproliferation and loss of differentiation, we generated a tamoxifen-inducible IEC-specific *Mcl1* knockout mouse (i-*Mcl1*^ΔIEC^ mice). Importantly the phenotype of i-*Mcl1*^ΔIEC^ mice closely recapitulated the phenotype of *Mcl1*^ΔIEC^ mice. The epithelium of i-*Mcl1*^ΔIEC^ mice displayed architectural disarray with crypt hyperplasia, villous atrophy (small intestine), increased IEC apoptosis, and IEC hyperproliferation throughout the small intestine and the colon ([Figure 5](#fig5){ref-type="fig"}*A*, [Supplementary Figure 14](#appsec1){ref-type="sec"}*A*). i-*Mcl1*^ΔIEC^ mice also displayed impaired epithelial barrier function and a markedly increased immune infiltration (3--4 days post induction) ([Supplementary Figure 14](#appsec1){ref-type="sec"}*A--C*). ISC differentiation to secretory lineages was also significantly reduced in i-*Mcl1*^ΔIEC^ mice, illustrated by a marked reduction in both goblet and Paneth cells following *Mcl1* deletion ([Figure 5](#fig5){ref-type="fig"}*B*). In addition, i-*Mcl1*^ΔIEC^ mice also displayed strong γH2AX positivity, detectable throughout the small intestine and colon following *Mcl1* deletion ([Figure 5](#fig5){ref-type="fig"}*B*). In addition, GSEA (from RNASeq data), indicated a strong enrichment for genes commonly upregulated in response to the detection of DNA damage and postreplication DNA repair in i-*Mcl1*^ΔIEC^ mice compared with littermate controls ([Figure 5](#fig5){ref-type="fig"}*C* and [Supplementary Figure 15](#appsec1){ref-type="sec"}*A*). These data further corroborated that the γH2AX positivity associated with *Mcl1* deletion was indeed indicative of DNA damage.Figure 5MCL1 protects the small intestine from activating WNT signaling and DNA damage. (*A* and *B*) Representative images from the small intestine of i-*Mcl1*^ΔIEC^ mice and age-matched controls (4 days post induction) (scale bars: 100 μm, 25 μm-insert). (*C*) GSEA carried out on RNASeq data from i-*Mcl1*^ΔIEC^ mice compared with littermate controls. (*D*) GSEA analysis tested for WNT target genes commonly upregulated in human CRC (*upper*) or in i-*Apc*^ΔIEC^ mouse models (*lower*). (*E*) BrdU staining from the small intestines of wild-type, i-*Ctnnb1*^ΔIEC/wt^, i-*Mcl1*^ΔIEC^, and i-*Ctnnb1*^ΔIEC/wt^*Mcl1*^ΔIEC^ mice, 4 days post induction (scale bars: 100 μm). Quantification of BrdU staining (positive cells/half crypt) is shown below (n = 3). (*F*) BrdU staining from the small intestines of vehicle-treated wild-type and i-*Mcl1*^ΔIEC^ mice compared with their WNT974-treated counterparts, 3 days post induction (scale bars: 100 μm). Quantification of BrdU staining (positive cells/half crypt) is shown below (n = 3). (*G*) Representative images from the small intestine of *Mcl1*^ΔIEC^ mice visualizing *Wnt2b* expression in *Mcl1*-positive versus *Mcl1-*deficient IECs using smFISH. *White dots* represents single molecules of *Wnt2b* and *red dots* represent *Mcl1.* ∗Indicates overexposed nonspecific signal. *Green dashed lines* represent the perimeter of intestinal crypts (scale bars: 25 μm-lower magnification, 10 μm-higher magnification). All data presented as scatter plot graph represents mean values ± SEM. Statistical analysis was conducted by Mann-Whitney test (*E* and *F*) where ∗*P* ≤ .05.

i-*Mcl1*^ΔIEC^ mice displayed complete *Mcl1* recombination throughout the entire intestine (compared with the "patchy" recombination described in *Mcl1*^ΔIEC^ mice) and so represented a valuable tool by which to more accurately investigate the molecular consequences to *Mcl1* deletion ([Supplementary Figure 16](#appsec1){ref-type="sec"}*A*). Interestingly, i-*Mcl1*^ΔIEC^ mice displayed a strong activation of wound-healing programs and increased expression of WNT target genes as determined by RNASeq analysis ([Supplementary Tables 13 and 14](#appsec1){ref-type="sec"}). Moreover, following *Mcl1* deletion, GSEA also indicated an enrichment for genes commonly upregulated in human colorectal cancer (CRC), as well as mice with an IEC-specific deletion of adenomatous polyposis coli (*Apc*), a prototypical model for intestinal tumorigenesis[@bib29] ([Figure 5](#fig5){ref-type="fig"}*D* and [Supplementary Figure 14](#appsec1){ref-type="sec"}*D*). To test whether MCL1 deficiency--associated hyperproliferation observed within the ISC compartment was dependent on WNT signaling, we co-deleted a single copy of the canonical WNT pathway mediator *Ctnnb1* (β-catenin) in conjunction with *Mcl1* (i-*Ctnnb1*^ΔIEC/wt^*Mcl1*^ΔIEC^ mice). Deleting a single copy of *Ctnnb1* was sufficient to partially rescue the hyperproliferative phenotype associated with *Mcl1* deletion ([Figure 5](#fig5){ref-type="fig"}*E* and [Supplementary Figure 17](#appsec1){ref-type="sec"}*A*). Subsequently, i-*Mcl1*^ΔIEC^ mice were treated with the WNT signaling/porcupine inhibitor WNT974. Strikingly, WNT974 treatment completely ameliorated hyperproliferation within the crypts of both the small intestine and colon of i-*Mcl*1^ΔIEC^ mice ([Figure 5](#fig5){ref-type="fig"}*F*, [Supplementary Figures 17](#appsec1){ref-type="sec"}*B* and 18*A* and *B*). Collectively, these data suggest that the impaired intestinal homeostasis following *Mcl1* deletion inflicts a WNT-induced hyperproliferative state on undifferentiated IECs.

To determine whether increased WNT signaling observed following *Mcl1* deletion was a direct or indirect consequence of *Mcl1* deletion, we next used smFISH to visualize *Wnt2b* molecules within the stroma of *Mcl1*^ΔIEC^ mice. First, *Wnt2b* expression levels were markedly increased within the stroma of damaged areas (*Mcl1*-deficient) compared with unaffected areas (*Mcl1*-expressing) ([Figure 5](#fig5){ref-type="fig"}*G* and [Supplementary Figure 19](#appsec1){ref-type="sec"}*A* and *B*). Second, IECs did not express *Wnt2b* irrespective of *Mcl1* expression. *Wnt2b* expression was completely restricted to the pool of *Mcl1*-positive cells within the stroma surrounding the intestinal crypts ([Figure 5](#fig5){ref-type="fig"}*G* and [Supplementary Figure 19](#appsec1){ref-type="sec"}*A* and *B*).

To delineate a potential effect of MCL1 deficiency in driving IEC proliferation from the effect of increased WNT signaling, we next generated a tamoxifen-inducible knockout mouse that facilitated the simultaneously delete both *Mcl1* and the essential negative regulator of WNT signaling *Apc* (i-*Apc*^ΔIEC^*Mcl1*^ΔIEC^ mice). As previously described, *Apc* deletion (i-Apc^ΔIEC^ mice) resulted in increased crypt proliferation and subsequent hyperplasia as a result of constitutive WNT signaling ([Figure 6](#fig6){ref-type="fig"}*A*). Remarkably, co-deletion of *Apc* and *Mcl1* resulted in a further significant increase in crypt proliferation throughout the small intestine and colon ([Figure 6](#fig6){ref-type="fig"}*A*). RNASeq analysis from these mice also showed significantly higher expression of essential proliferation associated genes *Pcna*, *Cdk1*, *Cdk4*, and *E2f1*, as well as marked increases in *Ccnd1* and *cMyc*, which was not attributable to activated WNT signaling ([Figure 6](#fig6){ref-type="fig"}*B* and *D* and [Supplementary Figure 20](#appsec1){ref-type="sec"}*A--C*). Similar to Mcl1^ΔIEC^ mice, IEC proliferation was intrinsically linked to increased apoptosis irrespective of the increased WNT signaling ([Supplementary Figure 20](#appsec1){ref-type="sec"}*D*). These results demonstrate that even in the presence of constitutive WNT signaling, the loss of *Mcl1* directly increases IEC proliferation beyond the levels obtained by WNT signaling alone.Figure 6MCL1 is an essential regulator of IEC proliferation. (*A*) Representative images of small intestinal or colonic tissue from i-*Apc*^ΔIEC^ and i-*Apc*^ΔIEC^*Mcl1*^ΔIEC^ mice (3 days post induction), and stained with hematoxylin and eosin (H&E) or for BrdU (scale bar: 50 μm). Quantification of BrdU-positive cells per half crypt from small intestine and colon (*right*). Normalized expression of *Pcna* (*B*), *Cdk1* (*C*), and *Cdk4* (*D*) in whole small intestine tissue from wild-type controls and i-*Mcl1*^ΔIEC^ mice (4 post induction), or i-*Apc*^ΔIEC^ and i-*Apc*^ΔIEC^*Mcl1*^ΔIEC^ mice (3 post induction) and analyzed by RNASeq (n = 3 per group). (*E*) Normalized expression of *Mcl1* in whole small intestinal tissue at day 4 post induction (*left*) or small intestine--derived organoids at passage ≥3 (*right*) from wild-type or i-*Mcl1*^ΔIEC^ mice as analyzed by RNASeq (n = 3 per group). (*F*) Relative expression of *Mcl1* in whole small intestinal tissue at day 3 post induction (*left*) or small intestine--derived organoids at passage ≥5 (*right*) in i-*Apc*^ΔIEC^ or i-*Apc*^ΔIEC^*Mcl1*^ΔIEC^ mice as analyzed by RNASeq (n = 3 per group). (*G*) Representative images of small intestine--derived organoids from i-*Apc*^ΔIEC^ or i-*Apc*^ΔIEC^*Mcl1*^ΔIEC^ mice (100x). All data presented as scatter plot graph represents mean values ± SEM. Statistical analysis was conducted by 1-tailed Mann-Whitney test where ∗*P* ≤ .05.

Despite the clear growth advantage observed in MCL1-deficient ISC in vivo, it was surprisingly not possible to establish a viable line of *Mcl1*-deficient organoids from *Mcl1*^ΔIEC^ mice. Interestingly, although it was possible to establish a low yield of organoids from the small intestine of i-*Mcl1*^ΔIEC^ mice, the organoids that formed had escaped recombination and retained *Mcl1* expression ([Figure 6](#fig6){ref-type="fig"}*E*). Remarkably, organoids derived from the small intestine of i-*Apc*^ΔIEC^*Mcl1*^ΔIEC^ mice were viable and retained *Mcl1* deficiency through at least 5 passages ([Figure 6](#fig6){ref-type="fig"}*F--G* and [Supplementary Figure 21](#appsec1){ref-type="sec"}*A*). These observations suggest that the activation of WNT signaling and subsequent WNT saturated environment is essential for the survival of MCL1-deficient ISCs. Collectively, these results not only demonstrate that MCL1 deficiency is intricately linked to an activated WNT signaling pathway, but that a clear proliferation-enhancing effect exists that is directly attributable to MCL1 deficiency.

*MCL1* Deficiency Results in Carcinoma Development {#sec2.6}
--------------------------------------------------

Given the increased proliferation and undifferentiated state of MCL1-deficient ISCs, together with the intestinal polyps observed in 4-month-old *Mcl1*^ΔIEC^ mice ([Figure 1](#fig1){ref-type="fig"}*A*), we next aimed to monitor the long-term sequelae of MCL1 deficiency. Strikingly, we found that lifelong MCL1 deficiency resulted in intestinal tumorigenesis ([Figure 7](#fig7){ref-type="fig"}*A*). By 1 year, \>80% of *Mcl1*^ΔIEC^ mice displayed intestinal neoplasms within the small intestine and/or colon. Remarkably, intestinal tumors developed with similar incidence under both SPF and germ-free conditions, therefore independently of microbe-induced intestinal inflammation ([Figure 7](#fig7){ref-type="fig"}*B*). Lesions comprised a spectrum ranging from hyperplastic changes over low- and high-grade adenomas to invasive carcinomas,[@bib20] thus mirroring Fearon and Vogelstein's[@bib30] adenoma-carcinoma-sequence of human intestinal carcinogenesis ([Figure 7](#fig7){ref-type="fig"}*C*, [Supplementary Figure 22](#appsec1){ref-type="sec"}*A*). Carcinoma found in *Mcl1*^ΔIEC^ mice extended deep into the *muscularis propria* (black box) and infiltrated intestinal vasculature (black circle) ([Figure 7](#fig7){ref-type="fig"}*C*). Of note, tumors were consistently MCL1 deficient and multiclonal in origin as shown by lineage tracing with the multicolor Cre-reporter R26R-Confetti[@bib31] ([Figure 7](#fig7){ref-type="fig"}*D* and [Supplementary Figure 22](#appsec1){ref-type="sec"}*B*). MCL1-deficient tumors also displayed inter- and intratumoral heterogeneity with respect to differentiation markers such as CD44, CDX2, and synaptophysin ([Supplementary Figure 22](#appsec1){ref-type="sec"}*C*). Furthermore, tumors displayed regional *Axin2* positivity and β-catenin nuclear localization indicating responsiveness to active WNT signaling and/or *Ctnnb1* mutations ([Figure 7](#fig7){ref-type="fig"}*E* and *F* and [Supplementary Figure 22](#appsec1){ref-type="sec"}*D*).Figure 7MCL1 protects from intestinal carcinoma development. (*A*) Representative images from colonoscopies (*top*), macroscopic imaging (*bottom*), and hematoxylin and eosin (H&E) characterization of colon carcinoma found in 18-month-old *Mcl1*^ΔIEC^ mouse (scale bar: 500 μm) (*right*). (*B*) Percentage and classification of tumor lesions observed in 12-month-old SPF *Mcl1*^ΔIEC^ mice (n = 42) compared with germ-free *Mcl1*^ΔIEC^ mice (n = 12). *White sections*: no tumor lesions or mucosal hyperplasia, *light gray sections*: low-grade adenomas (LGA), *dark gray sections*: high-grade adenomas (HGA), *black sections*: carcinoma (CA). In cases where more than a single lesion was present, individual mice were classified according to the highest tumor lesion. (*C*) Immunohistochemical (IHC) staining illustrating the invasive growth of carcinoma in *Mcl1*^ΔIEC^ mice. Carcinoma cells, α-SMA negative (*black boxes*), and cytokeratin positive (*black arrowheads*), actively invade the *muscularis propria* of an 18-month-old *Mcl1*^ΔIEC^ mouse (scale bar: 100 μm scale bars). *Black circle* indicates vesicular invasion. (*D*) IHC analysis showing lack of MCL1 expression in tumors that develop in *Mcl1*^ΔIEC^ mice (scale bar: 100 μm-*upper*, 25 μm-*lower*). (*E*) ISH for WNT target gene *Axin2* (scale bar: 100 μm-*upper*, 50 μm-*lower*). (*F*) Representative IHC staining illustrating nuclear β-catenin localization (*white arrowheads*) observed in a carcinoma from a 12-month-old *Mcl1*^ΔIEC^ mouse (scale bar: 100 μm-*upper*, 25 μm-*lower*). *Below*, a heterozygous missense point mutation in a mutational hot spot region of exon 2 of *Ctnnb1* (NM_000075.6:c.98C\>T - p.Ser33Phe) (3/5 carcinomas sequenced). (*G*) Array comparative genomic hybridization (aCGH) analysis of tumors isolated from 12-month-old *Mcl1*^ΔIEC^ mice (from left to right: 8 carcinoma samples, 2 adenoma samples, and 2 unaffected samples from 18-month-old *Mcl1*^ΔIEC^ mice). (*H*) Synteny analysis comparing chromosomal aberrations in carcinomas from *Mcl1*^ΔIEC^ mice with human CRC (murine chromosomes: M1--M19; human chromosomes H1--H22). Statistical analyses for nonrandom distribution of matched copy number gains revealed *P* \< .0001 for both gains and losses.

While progressing through the adenoma-carcinoma-sequence, tumors increasingly displayed genomic alterations in terms of nonrecurrent chromosomal aberrations as determined by array comparative genomic hybridization, as well as single nucleotide variants as determined by whole exome and Sanger sequencing ([Figure 7](#fig7){ref-type="fig"}*G*). Remarkably, Synteny analysis revealed a statistically significant overlap of chromosomal gains and losses with those found in human CRCs (78.3% of gains and 69.8% of losses; [Figure 7](#fig7){ref-type="fig"}*H*).[@bib32] Strikingly, single nucleotide variants comprised functionally relevant mutations in genes of the WNT pathway frequently also mutated in human CRC, such as *CTNNB1, APC, FBXW7*, and *ARID1*[@bib30]^,^[@bib32]^,^[@bib33] ([Supplementary Figure 23](#appsec1){ref-type="sec"}*A*).

Collectively, these findings demonstrate that carcinogenesis in *Mcl1*^ΔIEC^ mice morphologically and genetically closely recapitulates human intestinal carcinogenesis.[@bib30]^,^[@bib33] Furthermore, because tumors develop under germ-free conditions, MCL1 deficiency--related tumorigenesis is uncoupled from microbiota-induced chronic inflammation, a well-established promoter of intestinal carcinogenesis.[@bib34]

Discussion {#sec3}
==========

In this study, we have identified an essential role for MCL1 in preserving intestinal homeostasis and preventing carcinoma formation, previously undescribed among BCL2 antiapoptotic family members. These findings, in particular the microbiota-independency of MCL1 deficiency--associated tumorigenesis, clearly demonstrate an essential role for MCL1 in preserving intestinal homeostasis. These results may have important implications for understanding the pathogenesis of apoptotic enterocolopathy, IBD, and CRC development.

Disturbances in epithelial barrier integrity due to dysfunctional IEC--intrinsic molecular circuits that control tissue homeostasis, renewal, and the repair of IECs are cardinal features of both apoptotic enterocolopathy and IBD. Remarkably, intestinal pathology due to IEC-specific MCL1 deficiency shared hallmark features with IBD, including barrier dysfunction, chronic inflammation, increased IEC apoptosis, hyperproliferation, and impaired ISC differentiation.[@bib1]^,^[@bib3]^,^[@bib5] Thus, *Mcl1*^ΔIEC^ mice may represent a pertinent preclinical model of both apoptotic enterocolopathy and IBD, while also opening up the possibility that (even a temporally restricted) dysregulation of MCL1 may contribute to the development of these, and similar, conditions.

Given the well-established increased risk for patients with IBD to develop intestinal carcinomas, which increases parallel to the duration and severity of their disease,[@bib35] it was interesting to discover that *Mcl1*^ΔIEC^ mice also spontaneously developed intestinal carcinomas. Remarkably, however, although chronic inflammation has been established as a major driver of intestinal carcinoma,[@bib35] MCL1 deficiency--related carcinoma formation was independent of microbe-induced chronic inflammation.

Given the multifaceted and crucial roles of MCL1,[@bib36] various mechanisms are conceivable to explain MCL1 deficiency--related tumorigenesis. Of note, tumor lesions observed in *Mcl1*^ΔIEC^ mice exhibited the full spectrum of human CRC development described by Fearon and Vogelstein,[@bib30] ranging from dysplastic crypts and low-grade adenoma to high-grade adenoma and carcinoma. Interestingly, tumors that developed as a result of MCL1 deficiency not only bear a striking similarity to human CRC, but revealed significant correlations with the subgroup of CRC characterized by active WNT signaling. These results indicate a potentially direct and immediate function for MCL1 in regulating IEC proliferation and suppressing tumor formation, the functional consequence of which becomes obvious in the presence of constitutive WNT signaling. This scenario not only explains the mutational spectrum observed in MCL1-deficient tumors, with clear enrichment of genes associated with WNT signaling,[@bib32] but also explains the differential viability observed in ex vivo organoid cultures derived from the intestines of i-*Mcl1*^ΔIEC^ mice compared with those derived from i-*Apc*^ΔIEC^*Mcl1*^ΔIEC^ mice. Ex vivo culture of *Mcl1-*deficient organoids was only possible with the added deletion of *Apc*, indicating that the survival of *Mcl1* deficient ISC is dependent on the cell-intrinsic activation of WNT signaling. At the same time, we clearly show that in the presence of constitutive WNT signaling, *Mcl1* has a direct role in regulating ISC proliferation.

MCL1-deficient ISCs, which retain OLFM4, *Lgr5*, and SOX9 positivity, did not differentiate into the secondary secretory lineages, as illustrated by a complete loss of both Paneth and goblet cells. This loss of differentiation is restricted to *Mcl1-*deficient (phenotypic) regions of *Mcl1*^ΔIEC^ mice. Interestingly, *Mcl1-*deficient ISCs showed a significant reduction of the transcription factor *Atoh1*, essential for the differentiation to secondary secretory lineages.[@bib27] However, ISC from *Mcl1*-expressing (nonphenotypic) areas retain high *Atoh1* expression levels and differentiate to Paneth and goblet cells at a rate similar to wild-type ISCs. The inability of MCL1-deficient ISCs to differentiate to secretory cells was also observed under germ-free conditions, removing the potential influence of chronic inflammation. Whether or not this reduced *Atoh1* expression is a direct result of MCL1 deficiency or is a secondary effect of a WNT signaling saturated environment deserves further investigation. These data suggest that MCL1 is essential for maintaining the strictly controlled balance between ISC proliferation and differentiation, and the polarization of ISCs toward a hyperproliferative state in the absence of MCL1 may facilitate genetic alterations predisposing to tumorigenesis.

In addition, the strong positivity of γH2AX following *Mcl1* deletion within *Mcl1*^ΔIEC^ and i-*Mcl1*^ΔIEC^ mice also may be important in the context of tumor formation, and further studies are required to determine the significance of this observation. These γH2AX-positive cells potentially represent IECs that had accumulated DNA damage but escaped apoptotic programming. DNA damage is a well-established hallmark of tumorigenesis,[@bib28] and following *Mcl1* deletion*,* may originate from the increased replicative stress. The potential role of MCL1 in maintaining DNA replication integrity is very intriguing, and our findings support recent publications describing increased replicative stress and higher susceptibility to DNA double-strand breaks[@bib37]^,^[@bib38] and the strong synergistic effects of combining MCL1 and PARP-1 inhibitors to treat certain tumors.[@bib37]^,^[@bib39] Collectively, these recent findings strongly suggest a nonredundant role for MCL1 in maintaining DNA replication integrity, the absence of which may result in DNA damage and potentially tumor initiation, as observed in *Mcl1*^ΔIEC^ mice.

Conceptually, these findings show that, depending on the context, MCL1 dysregulation can promote tumorigenesis by different means. On one hand, although very rare in human cancers,[@bib40] it is conceivable that early steps of carcinogenesis may be induced by severely impaired intestinal homeostasis resulting from, even transient, gene alterations and loss of MCL1 function. On the other hand, amplifications of chromosome 1 resulting in overexpression of MCL1,[@bib36]^,^[@bib41] a recurrent finding in a variety of cancers including CRC, is well known to confer a survival advantage within tumors.[@bib42] Thus, pharmacologic inhibition of MCL1 recently has emerged as an attractive target to increase the susceptibility of different tumors to conventional antitumor therapies.[@bib39]^,^[@bib43]^,^[@bib44] Although recently published MCL1 inhibitors have been shown to be tolerable and functional in a number of different cancer models,[@bib45]^,^[@bib46] intestinal pathology due to pharmacological inhibition of MCL1 has not yet been extensively addressed. A complete lack of adverse effects within the intestinal epithelium would be surprising given the MCL1 dependency of IECs shown in this study.

In summary, we not only demonstrate the crucial role for MCL1 in maintaining intestinal homeostasis, but also uncover an unexpected tumor suppressor capacity for MCL1 within the intestinal tract. These findings may contribute to unravelling the early stages of intestinal cancer development, and may have important implications for current strategies aimed at pharmacologically targeting MCL1.[@bib45], [@bib46], [@bib47]
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